Cargando…
Notch activation inhibits AML growth and survival: a potential therapeutic approach
Although aberrant Notch activation contributes to leukemogenesis in T cells, its role in acute myelogenous leukemia (AML) remains unclear. Here, we report that human AML samples have robust expression of Notch receptors; however, Notch receptor activation and expression of downstream Notch targets a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570106/ https://www.ncbi.nlm.nih.gov/pubmed/23359069 http://dx.doi.org/10.1084/jem.20121527 |
_version_ | 1782259009136361472 |
---|---|
author | Kannan, Sankaranarayanan Sutphin, Robert M. Hall, Mandy G. Golfman, Leonard S. Fang, Wendy Nolo, Riitta M. Akers, Lauren J. Hammitt, Richard A. McMurray, John S. Kornblau, Steven M. Melnick, Ari M. Figueroa, Maria E. Zweidler-McKay, Patrick A. |
author_facet | Kannan, Sankaranarayanan Sutphin, Robert M. Hall, Mandy G. Golfman, Leonard S. Fang, Wendy Nolo, Riitta M. Akers, Lauren J. Hammitt, Richard A. McMurray, John S. Kornblau, Steven M. Melnick, Ari M. Figueroa, Maria E. Zweidler-McKay, Patrick A. |
author_sort | Kannan, Sankaranarayanan |
collection | PubMed |
description | Although aberrant Notch activation contributes to leukemogenesis in T cells, its role in acute myelogenous leukemia (AML) remains unclear. Here, we report that human AML samples have robust expression of Notch receptors; however, Notch receptor activation and expression of downstream Notch targets are remarkably low, suggesting that Notch is present but not constitutively activated in human AML. The functional role of these Notch receptors in AML is not known. Induced activation through any of the Notch receptors (Notch1–4), or through the Notch target Hairy/Enhancer of Split 1 (HES1), consistently leads to AML growth arrest and caspase-dependent apoptosis, which are associated with B cell lymphoma 2 (BCL2) loss and enhanced p53/p21 expression. These effects were dependent on the HES1 repressor domain and were rescued through reexpression of BCL2. Importantly, activated Notch1, Notch2, and HES1 all led to inhibited AML growth in vivo, and Notch inhibition via dnMAML enhanced proliferation in vivo, thus revealing the physiological inhibition of AML growth in vivo in response to Notch signaling. As a novel therapeutic approach, we used a Notch agonist peptide that led to significant apoptosis in AML patient samples. In conclusion, we report consistent Notch-mediated growth arrest and apoptosis in human AML, and propose the development of Notch agonists as a potential therapeutic approach in AML. |
format | Online Article Text |
id | pubmed-3570106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35701062013-08-11 Notch activation inhibits AML growth and survival: a potential therapeutic approach Kannan, Sankaranarayanan Sutphin, Robert M. Hall, Mandy G. Golfman, Leonard S. Fang, Wendy Nolo, Riitta M. Akers, Lauren J. Hammitt, Richard A. McMurray, John S. Kornblau, Steven M. Melnick, Ari M. Figueroa, Maria E. Zweidler-McKay, Patrick A. J Exp Med Article Although aberrant Notch activation contributes to leukemogenesis in T cells, its role in acute myelogenous leukemia (AML) remains unclear. Here, we report that human AML samples have robust expression of Notch receptors; however, Notch receptor activation and expression of downstream Notch targets are remarkably low, suggesting that Notch is present but not constitutively activated in human AML. The functional role of these Notch receptors in AML is not known. Induced activation through any of the Notch receptors (Notch1–4), or through the Notch target Hairy/Enhancer of Split 1 (HES1), consistently leads to AML growth arrest and caspase-dependent apoptosis, which are associated with B cell lymphoma 2 (BCL2) loss and enhanced p53/p21 expression. These effects were dependent on the HES1 repressor domain and were rescued through reexpression of BCL2. Importantly, activated Notch1, Notch2, and HES1 all led to inhibited AML growth in vivo, and Notch inhibition via dnMAML enhanced proliferation in vivo, thus revealing the physiological inhibition of AML growth in vivo in response to Notch signaling. As a novel therapeutic approach, we used a Notch agonist peptide that led to significant apoptosis in AML patient samples. In conclusion, we report consistent Notch-mediated growth arrest and apoptosis in human AML, and propose the development of Notch agonists as a potential therapeutic approach in AML. The Rockefeller University Press 2013-02-11 /pmc/articles/PMC3570106/ /pubmed/23359069 http://dx.doi.org/10.1084/jem.20121527 Text en © 2013 Kannan et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). |
spellingShingle | Article Kannan, Sankaranarayanan Sutphin, Robert M. Hall, Mandy G. Golfman, Leonard S. Fang, Wendy Nolo, Riitta M. Akers, Lauren J. Hammitt, Richard A. McMurray, John S. Kornblau, Steven M. Melnick, Ari M. Figueroa, Maria E. Zweidler-McKay, Patrick A. Notch activation inhibits AML growth and survival: a potential therapeutic approach |
title | Notch activation inhibits AML growth and survival: a potential therapeutic approach |
title_full | Notch activation inhibits AML growth and survival: a potential therapeutic approach |
title_fullStr | Notch activation inhibits AML growth and survival: a potential therapeutic approach |
title_full_unstemmed | Notch activation inhibits AML growth and survival: a potential therapeutic approach |
title_short | Notch activation inhibits AML growth and survival: a potential therapeutic approach |
title_sort | notch activation inhibits aml growth and survival: a potential therapeutic approach |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570106/ https://www.ncbi.nlm.nih.gov/pubmed/23359069 http://dx.doi.org/10.1084/jem.20121527 |
work_keys_str_mv | AT kannansankaranarayanan notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT sutphinrobertm notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT hallmandyg notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT golfmanleonards notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT fangwendy notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT noloriittam notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT akerslaurenj notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT hammittricharda notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT mcmurrayjohns notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT kornblaustevenm notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT melnickarim notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT figueroamariae notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach AT zweidlermckaypatricka notchactivationinhibitsamlgrowthandsurvivalapotentialtherapeuticapproach |